Objective: To evaluate the predictive value of GST gene polymorphisms with regard to prognosis of breastcancer patients receiving neoadjuvant chemotherapy.
Methods: A total of 159 patients were included in our studybetween January 2005 and January 2007. All the patients were followed up until January 2012. Genotypingwas based upon the duplex polymerase-chain-reaction with the PCR-CTPP method.
Results: Patients withnull GSTM1 and GSTP1 Val/Val genotypes had significantly had better response rates to chemotherapy whencompared with non-null GSTM1 and GSTP1 Ile/ Ile genotypes (OR=1.96 and OR=2.14, respectively). Patientswith the GSTM1 null genotype had a longer average survival time and significantly lower risk of death thandid those with non-null genotypes (HR=0.66). Similarly, those carrying the GSTP1 Val/Val genotype had 0.54-fold the risk of death of those with GSTP1 Ile/ Ile (HR=0.54).
Conclusion: A significant association was foundbetween GSTM1 and GSTP1 gene polymorphisms and clinical outcomes in breast cancer cases.